BMY Mar 2025 52.500 call
| Previous close | 0.6500 |
| Open | 0.6000 |
| Bid | 0.5600 |
| Ask | 0.6600 |
| Strike | 52.50 |
| Expiry date | 2025-03-21 |
| Day's range | 0.6000 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 39 |
ReutersBristol Myers to pay $2.7 million to settle Israel anti-competition charges
Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday. The anti-trust agency said that Bristol and Neopharm Scientific, the Israeli distributor of Imnovid - used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma - declined a request by KS Kim International for drug samples to make a copycat version of Imnovid.
ZacksInvestors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ZacksBristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
